Fuji to unveil slew of products at RSNA 2009
Fujifilm Medical Systems USA will unveil new products in computed and digital radiography, as well as digital mammography and information technology at the RSNA 2009 meeting.
Fujifilm Medical Systems USA will unveil new products in computed and digital radiography, as well as digital mammography and information technology at the RSNA 2009 meeting. Currently pending FDA clearance, its FDR (Fuji digital radiography) AcSelerate system features a fully automated table and upright stand and ergonomic design that the company say makes the system easier to use, position and operate than traditional systems.
Also debuting on the RSNA exhibit floor will be the company’s full field digital mammography (FFDM) system, Aspire-HD. Already in clinical use outside the U.S. but still pending FDA clearance, the Aspire HD offers a 24 x 30cm amorphous selenium detector that minimizes dose and produces images with low noise and high spatial resolution, utilizing pixels measuring 50 microns. A unique bucky design addresses patient comfort, while assuring optimal access to the chest wall. It will be configured with an FDA-pending color workstation, called the AWS c, which is designed to better illustrate patient data and image exposure information.
Fujifilm will also introduce its second generation of CR-based FFDM systems at RSNA 2009. This latest version of the Aspire ClearView reader will continue to provide 50 micron resolution and dual-side detector reading. Enhancements include a sleeker look, lighter weight, wider viewing angle on the LCD and the AWS c color workstation.
On the IT side, Fujifilm will show its Synapse cardiovascular version 4.0.4, a Web-based cardiovascular image and information management solution, featuring third party integrations that help clinicians access patient data stored in other locations. Interfaces to ViTALConnect for advanced 3D/4D analysis and GE MUSE Web, for access to ECG data are two new options. The enhanced Synapse product will also work with GE EchoPAC for import, storage and viewing of EchoPAC-created final reports and with Medis Medical QAngio XA for analysis of the left ventricle and coronary vessels in angiograms.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
